
HOME		SEARCH		RSS FEED		SUBSCRIBE

Search Results - db4xxx

52 Results

Sort By:

Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells

Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis and is associated with nearly 200,000 cancers and 140,000 deaths each year. EBV-associated cancers include Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt B cell lymphoma, and EBV post-transplant lymphoproliferative disease. The latent reservoir for EBV in the body is...

Published: 7/25/2024 | Inventor(s): Wei Bu, Nathan Board, Kennichl Dowdell, Jeffrey Cohen

Keywords(s): ANTIBODY, B, BLOCKS, Cells, DAXXXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DCXXXX, DDXXXX, DXXXXX, EPSTEIN-BARR, Fusion, Infection, Neutralizes, That, virus

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease

A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines

Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines...

Published: 7/25/2024 | Inventor(s): Roger Glass, Jean-Francois Saluzzo, Baoming Jiang

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Inactivation, Listed LPM Surabian as of 4/15/2015, NCIRD, OID-NCIRD-DVD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, rotavirus, thermal

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Therapeutics

Neutralizing Antibodies to Influenza HA and Their Use and Identification

The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe....

Published: 7/25/2024 | Inventor(s): Robert Bailer, Michael Joyce, John Mascola, Peter Kwong, Sarah Andrews, Paul Thomas, Gwo-Yu Chuang, Adam Wheatley, Yi Zhang, James Whittle, Adrian McDermott

Keywords(s): 1, 2, antibodies, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, GROUP, INFLUENZA, Neutralize, That, Their, Viruses, VLXXXX, WJXXXX, WNXXXX, XAXXXX, XKXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies, TherapeuticArea > Immunology

Chimeric Antibodies Against Hepatitis B e-Antigen

The invention relates to recombinant chimeric rabbit/human monoclonal antibody fragments (Fabs) against hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis is the seventh leading cause of death worldwide. Hepatitis B core antigen (HBcAg) forms an icosahedral structure containing the viral genome. Both the HBcAg and the HBeAg of interest...

Published: 7/30/2024 | Inventor(s): Norman Watts, Alasdair Steven, Paul Wingfield

Keywords(s): Against, antibodies, APPLICATIONS, assay, B, CHARACTERIZATION, chimeric, Chimic, DB4XXX, E-antigen, FAB, Hepalitis, Hepatitis, Potential, Rabbit/human, Their, THERAPY, VLXXXX, WJXXXX, XAXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, Application > Therapeutics, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies

Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2

Herpes simplex viral infections, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), are exceptionally common worldwide. These viruses establish lifelong persistent infections with cycles of lytic reactivation to produce recurrent diseases including oral and genital lesions, herpetic keratitis/blindness, congenital-developmental syndromes,...

Published: 7/25/2024 | Inventor(s): Jesse Arbuckle, Thomas Kristie

Keywords(s): DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DEXXXX, DXXXXX, EZH1/2, HERPESVIRUS, Infection, Inhibitors, Latency, Listed LPM Fenn as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reactivation, Suppresses, VLXXXX, WKXXXX, WNXXXX, XKXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines

CDC researchers have developed a potent immunogenic enhancer polypeptide useful for improving flavivirus vaccines. Flaviviruses such as dengue virus (1, 2, 3 and 4), Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, yellow fever virus and tick-borne encephalitis virus are a great burden on public health. ...

Published: 7/25/2024 | Inventor(s): Holly Hughes, Gwong-Jen Chang

Keywords(s): ADJUSTMENT, adjuvant, Adjuvant-like, BCXXXX, Boost, BOOSTING, CD4, CDC Docket Import, CDC Docket Import CDC Prosecuting, Cell, DB4BXX, DB4XXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DENGUE FEVER, Dengue Vaccine, Dengue-1, Dengue-2, Dengue-Like, DXXXXX, Epitope, Flavivirus, FLAVIVIRUSES, Identification, in vivo, JAPANESE ENCEPHALITIS VIRUS, Listed LPM Houze as of 4/15/2015, Mosquito, Mosquitoes, Nile, OID-NCEZID-DVBD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRIMER, T, THEREOF, Tick-Bone, TICK-BORNE, UBXXXX, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VBXXXX, Vector-borne, Vector-borne diseases, virus, VLXXXX, VOXXXX, WAXXXX, West, WIXXXX, WJXXXX, WMXXXX, XCXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines, Application > Therapeutics, Application > Research Materials, Application > Consumer Products, TherapeuticArea > Infectious Disease

Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination

This CDC-developed invention relates to dengue vaccines that have been specifically developed for improved efficacy and directed immune response to avoid antibody-dependent enhancement (ADE) safety issues that, theoretically, may be associated with dengue vaccines and vaccinations. Dengue viral infection typically causes a debilitating but non-lethal...

Published: 7/25/2024 | Inventor(s): Wayne Crill, Holly Hughes, Brent Davis, Gwong-Jen Chang

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, Containing, Cross-Reactive, DB4BXX, DB4XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DNA vaccine, DXXXXX, E-GLYCOPROTEIN, Eliminate, Epitopes, Immunodominant, insect, Insects, Mosquito, Mosquitoes, MULTIVALENT, Mutations, OID-NCEZID-DVBD, POLYPEPTIDES, Serotype, Serotypes, That, Vacccination, Vaccine, Vector-borne, Vector-borne diseases, virus, VLXXXX, WJXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Consumer Products, Application > Research Materials, Application > Diagnostics

Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein

This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein...

Published: 7/25/2024 | Inventor(s): Raffaello Cimbro, Paolo Lusso

Keywords(s): BETWEEN, CD4, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, Envelope, gp120, HIV, INHIBIT, INTERACTION, Mimics, Peptide, Protein, RECEPTOR, That, V2-loop, VLXXXX, WIXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX, YFXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Therapeutics, Application > Vaccines

Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response

This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated...

Published: 7/25/2024 | Inventor(s): Larry Anderson, Deborah Moore, Ralph Tripp

Keywords(s): bronchoilitis, CAUSED, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB3XXX, DB4XXX, DBXXXX, DISEASES, DXXXXX, IB3XXX, Infection, Inflammation, INFLAMMATORY, Methods, nitric oxide, OID-NCIRD-DVD, P, Pain, pain control, Prevention, Pulmonary, RESPONSE, RSV, RSV virus, SUBSTANCE, SUBSTANCE p, treatment, treatment methods, vasodilation, VASODILATOR, VAXXXX, VBXXXX, VDXXXX, VEXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Vaccines, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Geriatrics

CD40 Ligand: Adjuvant for Enhanced Immune Response to Respiratory Syncytial Virus

CDC researchers have developed methods and adjuvants for enhancing a subject's immune response to respiratory syncytial virus (RSV) by inclusion of a CD40 binding protein. RSV has long been recognized as a major respiratory tract pathogen of infants, as well as older children and the elderly. Established, successful methods for preventing RSV are...

Published: 4/8/2024 | Inventor(s): Larry Anderson, Michael Brown, Ralph Tripp

Keywords(s): adjuvant, CD40, CD40L, CDC Docket Import, CDC Docket Import CDC Prosecuting, Costimulation, COSTIMULATORY, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, LIGAND, OID-NCIRD-DVD, respiratory, RSV, RSV virus, Synctial, Vacccination, Vaccine, virus, VLXXXX, WJXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines

1 2 3 4 5 6

|

|

|

© 2024. All Rights Reserved. Powered by Inteum